Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as KB407 (Nebulization)
KB407 · 1 trial · 1 indication
Number of adult subjects with treatment related adverse events as assessed by NCI-CTCAE v5
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (open label) | EXPERIMENTAL | A single administration of KB407 |
| Cohort 2 (open label) | EXPERIMENTAL | Two administrations of KB407 |
| Cohort 3 (open label) | EXPERIMENTAL | Four administrations of KB407 |
| Cohort 4 (open label) | EXPERIMENTAL | Four consecutive administrations of KB407 followed by weekly administration for up to 6 months |
| Name | Type | Description |
|---|---|---|
| KB407 (Nebulization) | BIOLOGICAL | Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR |
Inclusion Criteria: 1. The subject must have read, understood, and signed an Institutional Review Board/Ethics Committee (IRB/IEC) approved Informed Consent Form and must be able to and willing to follow study procedures and instructions 2. Subjects aged 18 years or older at the time of Informed Co...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
KB407 is an investigational therapy being developed for the treatment of Cystic Fibrosis. It is administered via nebulization and is currently in Phase 1 clinical development. The drug is designed to address the underlying genetic cause of the disease by targeting the CFTR gene.
KB407 targets the CFTR gene, which is the gene responsible for Cystic Fibrosis. By targeting this gene, KB407 aims to correct the underlying genetic defect that causes the disease. The therapy is delivered through nebulization and is currently being studied in a Phase 1 clinical trial.
KB407 is being developed by Krystal Biotech, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol KRYS. The company is conducting a Phase 1 clinical trial to evaluate KB407 for the treatment of Cystic Fibrosis.
KB407 is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of Cystic Fibrosis and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants in the United States.
KB407 is being evaluated in a Phase 1 clinical trial with the identifier NCT05504837, titled 'A Study Assessing KB407 for the Treatment of Cystic Fibrosis.' The trial is recruiting 20 participants aged 18 years and older in the United States and is currently in the recruiting stage.
Yes, KB407 is also known as KB407 (Nebulization), reflecting the method of administration. The drug is delivered via nebulization, which is a method of inhaling a mist to deliver medication directly to the lungs. This alternative name is used in clinical trial contexts.